ERBB2 and breast carcinoma: We demonstrated a significantly higher response rate (83%) with concurrent letrozole and chemotherapy in HR-positive, HER2-negative breast cancer compared with previous studies on chemotherapy alone, which showed a clinical response rate of 60–70% [24,25].